Skip to content

Vaxcyte, Inc. PCVX Prepaid & Other Current

Prepaid & Other Current at other companies

Moderna logo
ModernaMRNA
$348M-40.5%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$16.03M-4.3%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$720.8M+12.1%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s prepaid & other current?
Vaxcyte, Inc. (PCVX) reported prepaid & other current of $76.31M in Q1 2026.
How has Vaxcyte, Inc.'s prepaid & other current changed year-over-year?
Vaxcyte, Inc.'s prepaid & other current increased by 70.2% year-over-year, from $44.83M to $76.31M.
What is the long-term trend for Vaxcyte, Inc.'s prepaid & other current?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s prepaid & other current has grown at a 46.7% compound annual growth rate (CAGR), from $47.76M to $221.43M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.